<DOC>
	<DOCNO>NCT02929901</DOCNO>
	<brief_summary>The purpose study investigate effect coffee main constituent ( caffeine chlorogenic acid ) supplement inflammatory , metabolic factor , hepatic steatosis fibrosis none- alcoholic fatty liver patient type 2 diabetes . Two hundred patient fatty liver type 2 diabetes randomly assign one four group : group 1 , caffeine ( 200 mg/d ) plus chlorogenic acid ( 200 mg/d ) ; group 2 , caffeine ( 200 mg/d ) plus placebo ; group 3 , chlorogenic acid ( 200 mg/d ) plus placebo ; group 4 , placebo plus placebo . Supplementation daily supervise 6 month .</brief_summary>
	<brief_title>The Effects Coffee Main Constituents ( Caffeine Chlorogenic Acid ) Supplementation Inflammatory , Metabolic Factors , Hepatic Steatosis Fibrosis None- Alcoholic Fatty Liver Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<criteria>Patient diagnose type 2 diabetes base American Diabetes Association ( ADA ) definition take oral antidiabetic drug . CAPscore &gt; 263 Criteria : Taking kind antibiotic two week recruitment ; History alcohol consumption ; pregnancy lactation ; Professional athlete ; Other liver disease ( viral/etc ) ; High dose synthetic estrogen , methotrexate , amiodarone , steroid , chloroquine , immunosuppressive drug ; A history Cardiovascular disease ; Renal disease , Celiac disease , Cirrhosis ; History Upper Gastrointestinal surgery ; A history hypothyroidism Cushing 's syndrome ; History drug dependence ; Body mass index ( BMI ) ≥35 kg/m2 ; A restrictive diet weight change ≥ 5 kg 3 month prior study ; Any change treatment oral hypoglycemic ; anti hypertensive antilipid agent study ; Use weight loss medication</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>